Synthesis and Preclinical Evaluation of Radiolabeled [103Ru]BOLD-100
The first-in-class ruthenium-based chemotherapeutic agent BOLD-100 (formerly IT-139, NKP-1339, KP1339) is currently the subject of clinical evaluation for the treatment of gastric, pancreatic, colorectal and bile duct cancer.A Training radiolabeled version of the compound could present a helpful diagnostic tool.Thus, this study investigated the pha